Tetradecylthioacetic Acid for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Tetradecylthioacetic Acid for Health & Longevity

Created on 06/27/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A lab-made fat-like molecule, designed with a sulfur atom so the body cannot burn it, acting instead as a long-lasting signal that switches on the cell's fat-burning and energy-building machinery. In animals it lowers blood fats, trims body fat, and calms inflammation, but it stays biologically interesting and clinically unproven, with human benefit and long-term safety unconfirmed. (Full Review)

Protocol

Standard dose range (as studied)
200–1000 mg/day
Phase 1 used single daily doses of 200, 600, or 1000 mg; supplement users commonly cite ~1000 mg (1 g) daily.
Best time of day
With meals
No circadian data; taken with meals to aid absorption of a fat-soluble compound, no morning-vs-evening advantage.
Single versus split dosing
Divided doses with meals
Divided doses with meals suggested for tolerability and absorption, though single daily dosing was used in the formal study.
Time to effect
Blood fats (animals)
Days to weeks
In animals, metabolic effects on blood fats develop over days to weeks of daily dosing.
Human lipid change
None within a week
In the brief human study no significant lipid change occurred within a week; any human benefit would likely require sustained dosing over weeks.

Benefits

Contraindications
  • Pregnancy
  • Breastfeeding
  • Children and adolescents
  • Active liver disease (e.g., Child-Pugh Class B or C)
  • Moderate-to-severe heart failure (NYHA Class III–IV)
  • Recent cardiovascular event
    •
Key Interactions
  • Lipid-lowering drugs (fibrates such as fenofibrate and gemfibrozil; statins)
  • Thiazolidinediones / glitazones (pioglitazone, rosiglitazone)
  • Anticoagulants and antiplatelet agents (warfarin, aspirin, clopidogrel)
  • Glucose-lowering drugs (insulin, sulfonylureas, metformin)
  • Over-the-counter agents (high-dose niacin, omega-3 fish oil)
  • Additive supplements (omega-3 EPA/DHA, berberine, red yeast rice, antioxidants)
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Mild, transient adverse events; hepatic lipid accumulation
    •
  • Speculative: Class-related PPAR agonist risks; mitochondrial proliferation / peroxisome effects; unknown long-term and reproductive safety
    •

Monitoring

Marker Target Why
Triglycerides < 80 mg/dL Primary expected target of TTA
Total / HDL / LDL cholesterol HDL > 50 mg/dL (women) / > 40 (men); LDL context-dependent Tracks lipoprotein remodeling toward larger HDL
ALT / AST (liver enzymes) ALT < 25 U/L; AST < 25 U/L Detects hepatic stress / lipid accumulation risk
Fasting glucose 70–85 mg/dL Detects insulin-sensitizing effect and hypoglycemia risk
HbA1c < 5.4% Longer-term glucose control if used for metabolic goals
Fasting insulin / HOMA-IR Insulin < 6 µIU/mL; HOMA-IR < 1.5 Assesses insulin sensitivity, the main animal benefit
hs-CRP < 1.0 mg/L Tracks anti-inflammatory effect

Cadence: Baseline before starting; recheck at roughly 4–8 weeks, then every 3–6 months if use continues.

Qualitative Assessment

  • Energy levels and perceived metabolic "flexibility" during fasting or exercise
  • Body weight and waist circumference trends
  • Any ankle swelling or unexplained rapid weight gain (possible fluid retention — a reason to stop)
  • General tolerability (digestive comfort when taken with meals)
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.